MedTrace Logo

Genomic Testing and Resulting Medical Decisions

NCT03301493 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2025-04-10

No results posted yet for this study

Summary

There is no evidence available about which molecular profiling methods are currently used for cancer patients in Austrian clinical practice. The construction of the registry proposed as a completely independent research endeavor, will be helpful for scientific evaluation and the establishment of highly credible data.

Conditions

  • Cancer of Unknown Origin
  • Cancer Refractory
  • Cancer of Stomach
  • Cancer Head Neck
  • Cancer of Skin
  • Cancer, Lung
  • Cancer Colorectal
  • Cancer of Esophagus
  • Cancer, Bladder
  • Cancer, Uterus
  • Cancer Cervix
  • Cancer Liver
  • Cancer, Kidney
  • Cancer, Breast
  • Hematologic Neoplasms

Interventions

OTHER

Genomic testing

Genomic profiling, indicated as assessed by the medical need and as deemed appropriate by the physician according to routine practice

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • AstraZeneca

    collaborator INDUSTRY

  • Arbeitsgemeinschaft medikamentoese Tumortherapie

    lead OTHER

Principal Investigators

  • Richard Greil, MD · IIIrd Medical Department, Private Medical University Hospital Salzburg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-30
Primary Completion
2023-12-31
Completion
2024-11-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03301493 on ClinicalTrials.gov